What ingredients does Evantumumab/Carestream contain?

Amivantamab (amivantamab) is a targeted drug with a unique molecular design. Its composition and structure determine its special status in tumor treatment. Unlike traditional small molecule targeted drugs, Carestream is a bispecific antibody, which means that it can act on two different receptors at the same time, namely EGFR (epidermal growth factor receptor) and MET (mesenchymal epithelial transforming factor receptor). This dual mechanism of action can block tumor signaling more effectively, especially for non-small cell lung cancer with EGFR exon 20 insertion mutations. Patients with such mutations are often resistant to traditional EGFR inhibitors, and the emergence of Carestream just fills this clinical gap.

From a composition perspective, evantumumab is a low-fucosylated human immunoglobulin G1 type (IgG1) bispecific antibody. It is produced through recombinant DNA technology using a mammalian cell line (Chinese Hamster Ovary Cells, CHO for short), with a molecular weight of approximately 148 kilodaltons. The drug is supplied as an injectable solution, usually a colorless to pale yellow clear solution, without preservatives, with each vial containing 350 mg of active ingredient at a concentration of 50 mg/ml and a pH of approximately 5.7. This preparation form ensures the stability and safety of the drug during intravenous infusion, while avoiding the adverse effects of impurities or preservatives.

The molecular design of evantumumab also takes into account the impact of antibody glycosylation on immune effects. Hypofucosylation can enhance antibody-dependent cell-mediated cytotoxicity (ADCC), making it more advantageous in inhibiting tumor cells. This characteristic also makes it not only a simple receptor blocker in clinical application, but also able to further eliminate cancer cells through immune effects. Compared with single-target drugs, evantumumab's dual mode of action and immune-enhancing properties have greatly improved its therapeutic potential and laid the foundation for its future combined use with other drugs.

Reference materials:https://www.rybrevant.com/